Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Heska Schedules Third Quarter 2018 Financial Results Conference Call for November 6, 2018

Heska Corporation
Posted on: 16 Oct 18
Heska Schedules Third Quarter 2018 Financial Results Conference Call for November 6, 2018

PR Newswire

LOVELAND, Colo., Oct. 16, 2018

LOVELAND, Colo., Oct. 16, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, plans to announce its third quarter 2018 financial results in a press release on Tuesday, November 6, 2018 before the market opens and to host a conference call on the results at 9 a.m. MT / 11 a.m. ET on the same day.

To access the conference call:

From within the United States, please dial 1-866-548-4713
From outside of the United States, please dial 1-323-794-2093
Reference Conference ID: 8134026

The conference call will be webcast live from the Company's website on

A telephonic replay of will be available beginning at 2 p.m. ET and continue through 11:59 p.m. ET on Tuesday, November 13, 2018. The webcast will be archived on for 90 days.

To access the replay:

From within the United States, please dial 1-844-512-2921
From outside the United States, please dial 1-412-317-6671
Reference Replay Pin Number: 8134026

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and healthcare products. Heska's Core Companion Animal Health ("CCA") segment represents approximately 80% of revenues and Other Vaccines, Pharmaceuticals and Products ("OVP") segment represents approximately 20% of revenues. CCA segment includes, primarily for canine and feline use, Point of Care Laboratory testing instruments and consumables under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit

View original content:

SOURCE Heska Corporation

PR Newswire

Last updated on: 16/10/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.